Skip to content

Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.

Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.

Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.

Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.

Published on

A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.

A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.